Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.

Linnemann, B; Greinacher, A; Lindhoff-Last, E

Linnemann, B; Greinacher, A; Lindhoff-Last, E.

Affiliation

Linnemann B; J. W. Goethe University Hospital, Frankfurt / Main, Germany. Birgit.Linnermann@kgu.de

Vasa ; 39(1): 103-7, 2010 Feb.

Article in En | MEDLINE | ID: mdl-20186683

Subject(s)

Behcet Syndrome/complications; Hirudins/adverse effects; Venous Thromboembolism/drug therapy; Adult; Antibodies/blood; Anticoagulants/adverse effects; Anticoagulants/pharmacokinetics; Dose-Response Relationship, Drug; Female; Heparin/therapeutic use; Hirudins/immunology; Hirudins/pharmacokinetics; Humans; Recombinant Proteins/adverse effects; Recombinant Proteins/immunology; Recombinant Proteins/pharmacokinetics; Recombinant Proteins/therapeutic use; Recurrence; Venous Thromboembolism/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Behcet Syndrome / Hirudins / Venous Thromboembolism Limits: Adult / Female / Humans Language: En Journal: Vasa Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google